971,253 Shares in Maplight Therapeutics, Inc. $MPLT Acquired by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 971,253 shares of the company’s stock, valued at approximately $17,060,000. Maplight Therapeutics comprises about 15.3% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 2nd biggest holding. Nan Fung Group Holdings Ltd owned 2.14% of Maplight Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strs Ohio purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth approximately $70,000. New York State Common Retirement Fund purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth approximately $93,000. MetLife Investment Management LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth approximately $172,000. Finally, Walleye Capital LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth approximately $205,000.

Insider Transactions at Maplight Therapeutics

In other news, CEO Christopher A. Kroeger sold 118,235 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $27.19, for a total value of $3,214,809.65. Following the transaction, the chief executive officer owned 1,394,094 shares of the company’s stock, valued at approximately $37,905,415.86. The trade was a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Anatol Kreitzer sold 45,422 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the completion of the transaction, the insider directly owned 211,190 shares in the company, valued at $6,263,895.40. This trade represents a 17.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 495,244 shares of company stock valued at $14,079,461. 3.80% of the stock is owned by corporate insiders.

Maplight Therapeutics Stock Performance

MPLT stock opened at $27.75 on Friday. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28. The company’s fifty day moving average price is $28.30 and its 200-day moving average price is $21.46. The company has a market capitalization of $1.18 billion and a PE ratio of -0.68.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). On average, research analysts predict that Maplight Therapeutics, Inc. will post -5.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MPLT shares. Lifesci Capital raised shares of Maplight Therapeutics to a “strong-buy” rating in a report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Maplight Therapeutics in a report on Thursday, May 28th. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They set a “buy” rating and a $35.00 price target on the stock. Craig Hallum started coverage on shares of Maplight Therapeutics in a report on Thursday, May 21st. They set a “buy” rating and a $43.00 price target on the stock. Finally, UBS Group started coverage on shares of Maplight Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $48.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $37.78.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.